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ABSTRACT.
Purpose: To summarize various topics and the cutting edge approaches to refine
XFS pathogenesis that were discussed at the 21st annual Glaucoma Foundation
Think Tank meeting in New York City, Sept. 19–20, 2014.
Methods: The highlights of three categories of talks on cutting edge research in
the field were summarized.
Results: Exfoliation syndrome (XFS) is a systemic disorder with a substantial
ocular burden, including high rates of cataract, cataract surgery complications,
glaucoma and retinal vein occlusion. New information about XFS is akin to
puzzle pieces that do not quite join together to reveal a clear picture regarding
how exfoliation material (XFM) forms.
Conclusion: Meeting participants concluded that it is unclear how the mild
homocysteinemia seen in XFS might contribute to the disarrayed extracellular
aggregates characteristic of this syndrome. Lysyl oxidase-like 1 (LOXL1)
variants are unequivocally genetic risk factors for XFS but exactly how these
variants contribute to the assembly of exfoliation material (XFM) remains
unclear. Variants in a new genomic region, CACNA1A associated with XFS,
may alter calcium concentrations at the cell surface and facilitate XFM
formation but much more work is needed before we can place this new finding in
proper context. It is hoped that various animal model and ex vivo systems will
emerge that will allow for proper assembly of the puzzle pieces into a coherent
picture of XFS pathogenesis. A clear understanding of XFS pathogenesis may
lead to ‘upstream solutions’ to reduce the ocular morbidity produced by XFS.
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Introduction
Exfoliation syndrome (XFS) is the
most common recognizable cause of
open-angle glaucoma worldwide,
accounting for the majority of cases
in some countries (Ritch 1994). It is a
public health problem because its ocu-
lar impact transcends open-angle glau-
coma to also include angle closure
glaucoma (Damji et al. 2009), a
keratopathy that involves all corneal
layers (Zheng et al. 2011), age related
cataract (Puska & Tarkkanen 2001), a
clinically significant zonulopathy
(Naumann 1988; Davis et al. 2009),
altered blood aqueous barrier integrity
that can manifest as a pseudouveitis
(Chern et al. 1994), and retinal venous
occlusive disease (Prata et al. 2010;
Ritch et al. 2010). Interestingly, XFS
deposits are recapitulated in organs
throughout the body (Schlotzer-
Schrehardt et al. 1992).
While much is known about the
clinical and histopathological features
of XFS (Ritch & Schlotzer-Schrehardt
2001), many questions remain unan-
swered. For example what is the earli-
est manifestation of the disease at the
ultrastructural and light microscopic
levels? How is exfoliation material
(XFM) assembled at the molecular
level? Why is the disease asymmetric
in a high percentage of cases? Could
there be factors in the fellow eye that
render it relatively impervious to XFM
deposition? While XFM deposits occur
in non-ocular tissue, one of the most
frequently described systemic clinical
finding is sensorineural hearing loss
(Cahill et al. 2002; Shaban & Asfour
2004; Aydogan Ozkan et al. 2006;
Turacli et al. 2007; Detorakis et al.
2008; Yazdani et al. 2008; Papadopou-
los et al. 2010, 2012; Paliobei et al.
2011); yet, most of these studies were
not performed in conjunction with
otologists, nor do they provide any
otopathological correlation. The sub-
ject of sensorineural hearing loss in
XFS deserves more carefully conducted
study in broader populations. While
XFM is located in many other organs
(Schlotzer-Schrehardt et al. 1992), the
clinical consequences of these deposits
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are equivocal. For example, reports on
an association with abdominal aortic
aneurysm (Schumacher et al. 2001;
Hietanen et al. 2002; Gonen et al.
2013) and cardiovascular disease
(Citirik et al. 2007; Sekeroglu et al.
2008; Emiroglu et al. 2010; Demir
et al. 2011) have been inconsistent
and while studies regarding association
with cerebrovascular disease exist
(Mitchell et al. 1997), there is no
evidence that XFS is associated with
increased risk of cardiac or all-cause
mortality (Ringvold et al. 1997; Shrum
et al. 2000; Tarkkanen & Kivela 2014;
Svensson & Ekstrom 2015). Discrep-
ancies between reports of critical end-
organ involvement and predicted rela-
tions with mortality could be the result
of study methodology or due to the
inconsequential amount of material
deposited in extraocular tissues. There
are new reports of several environmen-
tal exposures for XFS identified in
population-based studies (Stein et al.
2011; Pasquale et al. 2012; Kang et al.
2014a,b), two genetic susceptibility
markers (LOXL1 and CACN1A1)
(Thorleifsson et al. 2007; Aung et al.
2015) and two animal models that are
relevant to the disease process (Tran-
tow et al. 2009; Wiggs et al. 2014).
Think Tank participants engaged in a
discussion of these findings and how
they may shed light on the multiplicity
of unanswered questions about the
disease, with the goal of finding ways
to remove XFM, reverse its deposition
or inhibit its formation.
A combination of genetic and envi-
ronmental influences must create a
biochemical milieu conducive to the
formation of XFM. Homocysteine
and LOXL1 have emerged as factors
that may dysregulate extracellular
matrix metabolism in XFS. A new
genetic loci involved in calcium meta-
bolism (CACN1A1) has joined the list
of risk factors involved in the disease
process. Knowledge regarding plausi-
ble candidates contributing to XFM
creates the opportunity to recapitulate
XFM formation in a variety of model
systems.
What is the Role of
Homocysteine in
Exfoliation Syndrome?
Homocysteine (Hcy) is a well-studied
biomarker potentially related to XFS
(Vessani et al. 2003; Bleich et al. 2004;
Roedl et al. 2007;Xu et al. 2012).Hcy is
a non-protein amino acid that differs
from its homologue, cysteine due to an
additional CH2 bridging group. Hcy
levels are modestly, but consistently
higher in serum, aqueous humor and
tears of XFS patients compared to
controls. Hcy is not particularly con-
centrated in the anterior segment, the
most important site of ocular pathology
in XFS (Table 1). This raises questions
about whether this amino acid is a
disease driver, disease biomarker or an
innocent bystander to some biochemical
process related to Hcy metabolism.
If Hcy is a causative marker for
XFS, then genetic conditions that pro-
duce Hcy levels comparable to those
seen in XFS might be associated with
the disease. The common functional
C667T and A1298C polymorphisms in
the methylenetetrahydrofolate reduc-
tase (MTHFR) gene reduce enzymatic
activity for catalysing the conversion of
5,10-methyleneterathydrofolate to 5-
methyltetrahydrofolate, a co-substrate
for homocysteine re-methylation to
methionine producing mild hyperho-
mocysteinemia comparable to that seen
in XFS (Frosst et al. 1995; Weisberg
et al. 1998); yet, gene association stud-
ies fail to find an association between
these polymorphisms and XFS (Fan
et al. 2008; Xu et al. 2012). These data
do not support genetic variation as the
source of elevated Hcy in XFS,
although it is possible that these studies
were underpowered due to small sam-
ple sizes.
Rare Mendelian mutations in
MTHFR and cystathionine b-synthase
(CBS) can produce plasma Hcy levels
>300 lM (Kim et al. 1997) because
these patients are unable to remove
Hcy from the methionine – Hcy cycle
(Fig. 1). These patients have pheno-
typic features (severe myopia, ectopia
lentis, long limbs, arachnodactyly,
hyperlaxity thromboembolism, devel-
opmental delay and intellectual disabil-
ity) that share similarity with Marfan
syndrome but bear little resemblance to
XFS. Homocystinuria or CBS defi-
ciency is a rare autosomal recessive
disorder and while these patients gen-
erally have a shortened life span, no
association between this disorder and
XFS has been reported.
It is interesting to explore the effects
of Hcy on ECM proteins, given that
ECM metabolism is dysregulated in
XFS. Hcy has a high acid dissociation
constant (pKa = 10.0) relative to cys-
teine (pKa = 8.3) rendering it a highly
reactive nucleophile that forms strong
disulfide bonds (S-S) with cysteine (cys)
residues in proteins. In fact the disul-
phide bonds formed by R-S-S-Hcy
protein adducts are stronger than cys-
S-S-cys bonds, allowing Hcy to attack
disulphide bonds in proteins (Glush-
chenko & Jacobsen 2007). Thus, pro-
teins with high cysteine content such as
the fibrillins, and the associated
microfibrillar proteins, namely the fibu-
lins and latent TGF beta binding pro-
tein-2 (LTBP-2) (Downing et al. 1996),
are subject to transsulphuration by
high Hcy concentrations. Numerous
mutations in the fibrillin-1 gene
(FBN1) produce Marfan syndrome
(Davis & Summers 2012) and the
interaction between high Hcy concen-
trations and fibrillin-1 could produce
similar phenotypes. Hcy concentra-
tions of 300 lM completely abolish
calcium binding in the calcium binding
Epidermal Growth Factor domains in
fibrillin-1, rendering the protein highly
susceptible for proteolytic degradation
(Hubmacher et al. 2005). Furthermore
high Hcy levels reduce fibrillin-1 mul-
timer formation and impair fibrillin
self-interaction and assembly (Hub-
macher et al. 2010). This discussion is
highly relevant to the zonulopathy that
occurs in homocystinuria and Marfan






Plasma 15.5 11.8 0.012 Bleich et al. (2004)
Aqueous Humor 2.5 1.3 <0.0001 Bleich et al. (2004)
Plasma 14.5 10.2 <0.001 Roedl et al. (2007)
Tears 0.24 0.13 <0.001 Roedl et al. (2007)
Plasma
(meta-analysis of 14 studies)




syndrome in contrast with XFS, since
the zonule is composed predominately
of fibrillin-1 (Hubmacher et al. 2014).
In homocystinuria and Marfan syn-
drome the zonule is lax and elongates
(Maumenee 1981), whereas in XFS the
zonule is coated with XFM, frayed and
focally disrupted. These data indicate
that the shared phenotype features of
Marfan syndrome and homocystinuria
relate to the direct effect of fibrillin
gene mutations in the former and the
effect of Hcy modification on the
same gene product in the latter. The
zonulopathy in XFS, on the other hand
is probably unrelated to local Hcy
levels and may result from abnormal
lysosomal enzyme activity (Schlotzer-
Schrehardt & Naumann 1994).
If Hcy is not a causative marker in
XFS then exactly what is its role in
disease pathogenesis? Vitamin B6, vita-
min B12 and folic acid are important co-
substrates for proper functioning of the
methionine-Hcy cycle (Fig. 1). A syn-
thesis of the literature suggests that
serum folate levels are reduced in XFS
patients while vitamin B6 and vitamin
B12 are not (Xu et al. 2012). Further-
more, a large prospective dietary study
in the U.S. indicated that health profes-
sionals were consuming more than ade-
quate amounts of B6 and B12 but 50%
were deficient in folate intake (Kang
et al. 2014a). Furthermore, there was a
trend towards reduced dietary folate
intake (but not dietary B6 and B12) in
association with XFG (Kang et al.
2014a). Thus, a chronically unbalanced
methionine – Hcy cycle due to low
dietary folate intake could be important
in XFS. Chronic folate deficiency may
prevent Hcy from cycling back to
methionine, resulting in hypomethyla-
tion of key DNA loci (Fig. 1). The
consequence is that local epigenetic
mechanisms could cause altered LOXL1
expression and protein function, which
could result in abnormal cross-linking
of key macromolecules in XFM.
Immunohistochemistry has shown
LOXL1 as a component of XFM in
early disease stages (Zenkel et al. 2011;
Zenkel & Schlotzer-Schrehardt 2014).
Another byproduct of imbalanced Hcy-
methionine cycling is endothelial cell
dysfunction, which could account for
the increased retinal venous occlusive
disease and other vascular findings seen
in XFS (Hollo et al. 1998; Visontai
et al. 2006, 2008; Prata et al. 2010;
Ritch et al. 2010). It should be empha-
sized that the pieces of this complicated
puzzle may require re-arranging as more






Finding and characterizing genes that
cause or contribute to XFS can define
the underlying molecular events
responsible for disease, suggest novel
therapies targeting molecular patho-
physiology and lead to the develop-
ment of DNA-based diagnostic and
screening tests. While XFS is readily
diagnosed at the slit-lamp, a predictive
model that incorporates genetic data
creates an opportunity for preclinical
diagnosis, allowing for more effective
preventative intervention. A genome-
wide association study performed in
Iceland demonstrated that LOXL1
(lysyl oxidase like 1) is a major genetic
risk factor for XFS (Thorleifsson et al.
2007). LOXL1 is a cross-linking
enzyme necessary for elastin formation
and maintenance. The association of
LOXL1 with XFS has been replicated
in populations throughout the world
(Wang et al. 2014). Two missense
variants in exon 1, R141L and
G153D, were initially considered as
the source of increased risk for disease
in the locus. In fact the risk allele for
the G153D conferred a 20-fold
increased risk for XFS, an astound-
ingly high effect size for a common
variant. However, while risk alleles
were present in 99% of cases, they
are also present in up to 80% of
controls, suggesting that variants in
this genomic region are necessary but
not sufficient to produce disease. Fur-
thermore, while the effect size for the
G153D variant is high, the risk allele is
flipped from A coding for glycine
(labelled as G) to G coding for aspar-
tate (labelled as D) in a South African
population (Williams et al. 2010). The
functionality of the exon 1 gene vari-
ants is not entirely clear, prompting
researchers to explore the nearby pro-
moter region and other 50 regulatory
sequences for ‘causative’ variants
related to XFS. The promoter region
of LOXL1 is a particularly attractive
candidate region to discover such
variants because it contains many
potentially active regulatory sequences
that might influence gene expression
including a LOXL1 antisense RNA,
DNase hypersensitivity sites and DNA
methylation regions. LOXL1 promoter
Methionine - Homocysteine Cycle













Fig. 1. The methionine – homocysteine cycle contains re-methylation and transsulfuration
components. The enzyme S-adenosyl homocysteine hydrolase (SAH) contributes to methylation
of DNA and RNA. Other abbreviations: CBS = cystathionine–b–synthase; MTR = 5-methylter-
athydrofolate-homocyteine methyltransferase; MTHFR = methyltetrahydrofolate reductase;
THF-tetrahydrofolate; MTHF = methyltetrathydrofolate.
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region haplotypes are also associated
with XFS (Fan et al. 2011) but risk
alleles in this region are also flipped in
Asian populations (Dubey et al. 2014).
The flipping of risk alleles in exon 1
and the LOXL1 promoter region sug-
gests these variants are in linkage
disequilibrium with yet other nearby
loci that are important in XFS. Alter-
natively, the flipping of alleles at these
various regions may signify that these
are sites of local epigenetic methyla-
tion involved in regulating LOXL1
gene expression and risk for XFS.
Another issue to consider is that the
frequency of LOXL1 risk alleles does
not correlate with disease prevalence in
various populations. XFS prevalence
ranges from ~1% or less to >20% in
various populations, yet the ratio of
cases and controls with LOXL1 genetic
susceptibility loci is relatively constant
at ~95%: 70%, depending on which
locus one refers to (Pasquale et al.
2014).
While the search for other genetic
loci associated with XFS continues, it
does raise the possibility that the rela-
tion between LOXL1 gene variants is
modified by environmental influences.
From an epidemiological perspective,
gene environment (GxE) interactions
can be nonexistent (Figs 2–4) even if
there are genetic and environmental
influences that predict a trait of inter-
est. Alternatively, genetic effects could
be altered by the environment and
these effects can be additive, multi-
plicative or of the cross-over variety
(Figs 5 and 6, respectively). For one to
entertain GxE interactions in XFS, one
needs a cadre of environmental factors
to consider for analysis. Work regard-
ing the distribution of XFS as a func-
tion of geographical residence has
revealed that colder ambient tempera-
ture and ultraviolet exposure are
important environmental exposures in
this disorder (Stein et al. 2011). Other
possible environmental risk factors
include high caffeine consumption
(Pasquale et al. 2012) and low dietary
folate intake (Kang et al. 2014a).
While there is evidence for additive
(Kang et al. 2010) and cross-over GxE
interactions (Kang et al. 2011) in pri-
mary open-angle glaucoma, there is
currently no evidence for GxE interac-
tions in XFS.
A worldwide collaboration involving
a genome-wide association study from
Japan followed by two-stage replica-
tion using samples from 17 countries
confirmed the association with LOXL1
and identified a novel locus involved in
calcium signalling (CACNA1A) (Aung
et al. 2015). CACNA1A codes for the
transmembrane pore-forming subunit
of the P/Q calcium channel, important
for mediating calcium ion entry into
excitable cells. It is also plays an
important role in muscle contraction,
hormone or neurotransmitter release
and gene expression. The gene is
expressed in ocular tissues relevant to
XFS but is not found in XFM itself.
High concentrations of calcium in
XFM (Schlotzer-Schrehardt et al.
2001) has been reported and it is
possible that alterations in cell surface
calcium ions could facilitate the devel-
opment of manifest disease. The con-
nection between these observations, the
CACNA1A gene, and the pathogenesis
of XFS is not yet known.
Animal Models of
Exfoliation Syndrome
A viable animal model of XFS could
generate sufficient quantities of XFM
for biochemical analysis. It has not
been possible to generate XFM
ex vivo and only small amounts can
Fig. 2. Model of how genes and environment
might contribute to risk of exfoliation syn-
drome (XFS): Pure environmental effect on
XFS. Abbreviations: G1 = genotype 1;
G2 = genotype 2; E1 = environmental expo-
sure level 1; E2 = environment exposure level
2; GE = gene-environment interaction term; d
is a constant; b1, b2 and b3 are coefficients that
indicate the effect size for the respective
genetic, environment and gene-environment
interaction terms. NB: The same abbreviations
are used for figures 3 through 6.
Fig. 3. Model of how genes and environment
might contribute to risk of exfoliation syn-
drome (XFS): Pure genetic effect.
Fig. 4. Model of how genes and environment might contribute to risk of exfoliation syndrome




be retrieved from surgical specimens
or post-mortem material. Animal
models would allow researchers to
study the pathophysiology of XFS
and how XFM forms. Such models
could also confirm the role of envi-
ronmental factors in influencing dis-
ease development and assess the
efficacy of novel therapeutics to rescue
the phenotype.
Models of XFS need not mimic all
facets of the disease, but probably the
aspect that is critically important to
recapitulate is the ocular deposition of
XFM. Model resources currently
available are the Loxl1 knock-out
mouse (Wiggs et al. 2014) and the
Lyst mouse (Trantow et al. 2009).
Both models are intriguing but both
have their shortcomings. The Loxl1
(/) mouse develops cataract and
has blood aqueous barrier dysfunction
but there is no XFM, increased
intraocular pressure (IOP) or optic
neuropathy. The Lyst mouse (B6-
Lystbg-J) harbours a three base pair
deletion that removes a single isoleu-
cine from the carboxy terminus of the
Lyst protein. Lyst codes for a lysoso-
mal trafficking regulator and muta-
tions in Lyst produce Chediak Higashi
syndrome, a condition categorized by
oculocutaneous albinism, immune sys-
tem defects and abnormal clotting
(Nagle et al. 1996). The mutation in
these mice recapitulates the saw tooth
iris transillumination defects seen in
humans. There are XFM-like deposits
but electron microscopy is required to
see them. These mice also do not
develop elevated IOP or glaucoma.
CACNA1A null mice exhibit dystonia
and cerebellar atrophy but the ocular
phenotype is not known (Fletcher
et al. 2001). Collectively these new
models indicate that some LOXL1
enzymatic is probably needed to gen-
erate XFM and that more research





To find the earliest clinical manifesta-
tion of XFS, it may be helpful to
perform a mass screening of lens cap-
sular specimens from patients with and
without slit lamp biomicroscopic evi-
dence of XFS according to an agreed
upon experimental protocol that would
involve immunohistochemistry and
electron microscopy. Histological com-
parisons between pairs of human
donor eyes from patients with unilat-
eral or asymmetric disease might also
provide novel insights into the patho-
genesis of XFS.
The role of LOXL1 gene variants in
XFS requires more attention. There-
fore, deep re-sequencing efforts are
needed to identify the specific muta-
tions in the LOXL1 locus that confer
risk for XFS. More work is needed to
understand the cell biology of LOXL1
in the eye. We know that LOXL1
orchestrates elastogenesis by binding
its N terminus to fibulin 5. Perhaps
CRISPR – caspase 9 technology can be
used to cleave the N terminus of
Fig. 5. Models of how genes and environment might contribute to risk of exfoliation syndrome
(XFS): Left: An illustration of how the risk of XFS might be influenced by an additive gene-
environment interaction; Right: An illustration of how the risk of XFS might be influenced by a
multiplicative gene-environment interaction.
Fig. 6. Model of how genes and environment might contribute to risk of exfoliation syndrome




LOXL1 in the anterior segment to
explore the phenotypic consequences.
Other alternatives to learn about the
cell biology of LOXL1 include the use
of a rapidly aged, humanized droso-
phila model where the human LOXL1
gene variants can be inserted to study
alterations in ocular phenotype. This
approach has been used with success in
Parkinson’s Disease (Siddique et al.
2014). Induced pluripotent stem (iPS)
cells could also be used to model XFS
and study LOXL1 biology. New
growth factor cocktails produce better
quality iPS cells and this approach has
been used to model retinitis pigmentosa
(Tucker et al. 2013). However, there
are challenges for modelling XFS in
this manner including the need to
induce terminal differentiation of the
eye cup into ciliary body and iris, as
XFM has never been found in retinal
tissue.
Most candidate genes, including
candidate loci involved in the
methionine-Hcy cycle are not associ-
ated with XFS. However, there is a
suggestion that a locus in CLU may
be associated with XFS (Krumbiegel
et al. 2009; Padhy et al. 2014). CLU
encodes the protein clusterin, a chap-
erone highly expressed in the human
iris that co-localizes with XFM
(Doudevski et al. 2014). More work
is needed to discover new XFS genes
and this work is proceeding rapidly.
Work in this area will require sample
sizes on the order of 5000–10 000
cases to completely define the genetic
architecture for XFS. The discovery
of new XFS genes could spawn new
XFS animal models that faithfully
replicate the disease.
The future for assembling the puzzle
pieces into a clear picture of XFS
pathophysiology is bright. We need to
look inside any cell that is destined to
make XFM and understand how it is
different from a normal cell. Explo-
ration of extreme phenotypes, namely
patients who develop the disease at a
young age, may be helpful. The theme
of case reports regarding young age of
onset XFS suggests that cellular stress
could play a critical role in XFM
formation (Konstas et al. 1997; Amini
et al. 2012). It will be important to
incorporate cellular stress simulations
in model systems of XFS moving
forward. The long-term goal is to cure
XFS by strategies that prevent or
disassemble XFM at an early stage
before ocular morbidity is realized.
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The Glaucoma Foundation held a meeting
entitled, ‘Exfoliation Syndrome: Tying It All
Together’ in New York, NY, September 19–
20, 2014. The meeting organizers and moder-
ators were R. Rand Allingham, MD (Profes-
sor of Ophthalmology, Duke University
Medical Center, Durham, NC), Louis R.
Pasquale, MD (Professor of Ophthalmology,
Mass Eye and Ear Infirmary, Harvard Med-
ical School, Boston, MA), Terete Borras, PhD
(Professor of Ophthalmology, University of
North Carolina, Chapel Hill, NC;), John H.
Fingert, MD, PhD (Associate Professor, Oph-
thalmology and Visual Science, University of
Iowa, Iowa City, Iowa), Richard T. Libby,
PhD (Associate Professor, Flaum Eye Insti-
tute, University of Rochester School of
Medicine, Rochester, NY), Janey L. Wiggs,
MD, PhD (Professor of Ophthalmology,
Mass Eye and Ear Infirmary, Harvard Med-
ical School, Boston, MA), Barbara Wirostko,
MD (Clinical Adjunct Associate Professor,
Moran Eye Center, University of Utah School
of Medicine, Salt Lake City, UT) and Robert
Ritch, MD (Professor of Ophthalmology,
Einhorn Clinical Research Center, New York
Eye and Ear Infirmary of Mount Sinai, New
York, NY).
Meeting participants included Marianna
Alperin, MD, MS (Assistant Adjunct Profes-
sor, Department of Reproductive Medicine,
University of California, San Diego, La Jolla,
CA), Tin Aung, MMed, FRCS, FRCOphth,
FAMS, PhD (Professor of Ophthalmology,
Head and Senior Consultant, Glaucoma Ser-
vice, Singapore National Eye Center, Singa-
pore), Steven Bassnett, PhD (Professor,
Washington University School of Medicine,
St. Louis, MI), Audrey Bernstein, PhD
(Assistant Professor, Departments of Oph-
thalmology and Pharmacology and Sys-
tems Therapeutics Mt. Sinai School of
Medicine, New York, NY), Emmanuel Buys,
PhD (Assistant Professor, Department of
Anesthesia, Critical Care and Pain Medicine,
Massachusetts General Hospital, Harvard
Medical School, Boston, MA), Hemin Chin,
PhD (Director, Glaucoma & Optic Neu-
ropathies Program, Division of Extramural
Research, National Eye Institute, Rockville,
MD), Miguel Coca-Prados, PhD (Professor
(Adjunct) of Ophthalmology, Department of
Ophthalmology and Visual Sciences, Yale
University School of Medicine, New Haven,
CT), John Danias, MD, PhD (Professor of
Ophthalmology and Cell Biology, SUNY
Downstate Medical Center, Brooklyn, NY),
Terry Gaasterland, PHD (Professor, Compu-
tational Biology and Genomics, Institute for
Genomic Medicine, University of California,
San Diego, La Jolla, CA),
Michael Hauser, PhD (Professor of Medi-
cine, Ophthalmology & Medicine Depart-
ments, Duke University Medical Center,
Durham, NC), Donald Hood, MSc, PhD
(Professor of Psychology and Ophthalmology,
Columbia University, New York, NY), Dirk
Hubmacher, PhD (Project Scientist, Depart-
ment of Biomedical Engineering, Lerner
Research Institute, Cleveland Clinic, Cleve-
land, OH), Margaret E. Huflejt, PhD (Assis-
tant Professor, Department of Cardiothoracic
Surgery, NYU School of Medicine, New
York, NY), Paul L. Kaufman, MD (Profes-
sor, Department of Ophthalmology & Visual
Sciences, Univ. of Wisconsin School of
Medicine and Public Health, Madison, WI),
Chiea-Chuen Khor, MB, BS, DPhil (Senior
Investigator, Genome Institute of Singapore,
Singapore), Rachel Kuchtey, MD, PhD
(Associate Professor of Ophthalmology and
Visual Sciences, Vanderbilt University, Nash-
ville, TN), Markus H. Kuehn, PhD (Associate
Professor, Department of Ophthalmology and
Visual Sciences, University of Iowa, Iowa
City, IA), James F. Leary, PhD (Professor of
Nanomedicine, Purdue University, West
Lafayette, IN), Jeffrey M. Liebmann, MD
(Professor of Ophthalmology, Columbia
University Medical School, New York, NY),
Carlo D. Montemagno, PhD (Professor of
Chemical and Materials Engineering, Univer-
sity of Alberta, Alberta, Canada), Mineo
Ozaki, MD, PhD (Clinical Assistant Profes-
sor, University of Miyazaki, Miyazaki,
Japan), Qibin Qi, PhD (Assistant Professor,
Department of Epidemiology and Population
Health, Albert Einstein College of Medicine,
Bronx, NY). Dieter Reinhardt, PhD (Profes-
sor and Canada Research Chair in Cell-
Matrix Biology, Department of Anatomy
and Cell Biology, McGill University Quebec,
Canada), Daniel B. Rifkin, PhD (Professor of
Medicine, Dept. of Cell Biology, New York
University Langone Medical Center, New
York, NY), Sylvia Wassertheil-Smoller,
PhD, FAHA (Professor, Department of Epi-
demiology and Population Health, Albert
Einstein College of Medicine, Bronx, NY),
Jose M. Wolosin, PhD (Professor of Ophthal-
mology, Mount Sinai Hospital, New York,
NY), Ting Xie, PhD (Professor, Department
of Anatomy and Cell Biology, University of
Kansas Medical Center, Kansas City, MO).
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